ReviewDrug delivery2018
The glyconanoparticle as carrier for drug delivery.
Review in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Metabolic engineering of Escherichia coli strains for the in vivo phosphorylase-mediated synthesis of disaccharides.Microbial cell factories · 2026Article
- Next-generation Mesoporous Silica Nanoparticles: Precision-engineered Platforms for Ovarian Cancer Therapy.Current drug research reviews · 2026Review
- Emerging Trends in Microfluidic Biomaterials: From Functional Design to Applications.Journal of functional biomaterials · 2025Review
- Ferulic Acid-Loaded Nanostructure Maintains Brain Levels of ACh, Glutamate, and GABA and Ameliorates Anxiety and Memory Impairments Induced by the D-Galactose Aging Process in Rats.Neurochemical research · 2024Article
- Design and synthesis of unnatural coordination glycopolymer particles (CGPs): unleashing the potential of catechol-saccharide derivatives.RSC advances · 2023Article
- Interaction of sugar stabilised silver nanoparticles with Momordica charantia seed lectin, a type II ribosome inactivating protein.Glycoconjugate journal · 2023Article
- Green synthesis of glyco-CuInSJournal of nanobiotechnology · 2023Article
- Amino acid modified OCMC-g-Suc-Frontiers in pharmacology · 2023Article
- Carbon-based glyco-nanoplatforms: towards the next generation of glycan-based multivalent probes.Chemical Society reviews · 2022Review
- Recent advances in nanoparticle-based targeting tactics for antibacterial photodynamic therapy.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2022Review
- Human Lectins, Their Carbohydrate Affinities and Where to Find Them.Biomolecules · 2021Review
- Exploring Carbohydrates for Therapeutics: A Review on Future Directions.Frontiers in pharmacology · 2021Review
- Design of Engineered Cyclodextrin Derivatives for Spontaneous Coating of Highly Porous Metal-Organic Framework Nanoparticles in Aqueous Media.Nanomaterials (Basel, Switzerland) · 2019Article
- Fabrication, Investigation, and Application of Light-Responsive Self-Assembled Nanoparticles.Frontiers in chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The glyconanoparticle (GlycoNP) has multiple effects and has important applications in drug delivery and bioimaging. It not only has the advantages of nano drug delivery system but also utilizes the characteristics of multivalent interaction of sugar, which greatly improves the targeting of drug delivery. Herein, the application of GlycoNP in drug delivery was analyzed and discussed, the solution to its problem was proposed, and its prospects were forecasted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.